Affinity Chromatography: An Enabling Technology for Large Scale Bioprocessing

October 2021

BY

Frank RiskeManaging Director, Bioprocess Technology Group

Affinity chromatography has allowed the standardization of Mab manufacturing in the developed world. However, discovering and developing the appropriate ligand for non Mab’s requires specialized labs and equipment which may not be available in all parts of the world.

Developing markets have shown the interest, human capital and capacity to take part in the biotechnology industry. Companies are looking to these markets due to their affordability and their unmet medical need.

Read more about the developing world and affinity chromatography in a recent article from Bioprocess Technology Group Managing Director Frank Riske in the Journal of Biotechnology and Bioprocessing.